You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAzilsartan medoxomil
Accession NumberDB08822
TypeSmall Molecule
GroupsApproved
DescriptionAzilsartan medoxomil is an angiotensin II receptor antagonist indicated for the treatment of mild to moderate essential hypertension. Azilsartan medoxomil is a prodrug of Azilsartan marketed as "Edarbi" by Takeda. Azilsartan medoxomil has so far been shown to be superior to olmesartan and valsartan in lowering blood pressure.
Structure
Thumb
Synonyms
Azilsartan
Azilsartan kamedoxomil
Azilsartan medoxomilo
Azilsartanum medoxomilum
Edarbi
External Identifiers
  • TAK-491
  • TAK-536
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Edarbitablet40 mg/1oralTakeda Pharmaceuticals America, Inc.2011-02-25Not applicableUs
Edarbitablet40 mgoralValeant Canada Lp/valeant Canada s.e.c.2012-11-08Not applicableCanada
Edarbitablet80 mg/1oralTakeda Pharmaceuticals America, Inc.2011-02-25Not applicableUs
Edarbitablet80 mgoralValeant Canada Lp/valeant Canada s.e.c.2012-11-08Not applicableCanada
Edarbitablet40 mg/1oralArbor Pharmaceuticals2013-02-01Not applicableUs
Edarbitablet80 mg/1oralArbor Pharmaceuticals2013-02-01Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
EdarbyclorTakeda Pharmaceuticals America, Inc.
SaltsNot Available
Categories
UNIILL0G25K7I2
CAS number863031-21-4
WeightAverage: 568.5336
Monoisotopic: 568.159413764
Chemical FormulaC30H24N4O8
InChI KeyInChIKey=QJFSABGVXDWMIW-UHFFFAOYSA-N
InChI
InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)
IUPAC Name
(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 2-ethoxy-1-({4-[2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylate
SMILES
CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetracarboxylic acids and derivatives. These are carboxylic acids containing exactly four carboxyl groups.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassTetracarboxylic acids and derivatives
Direct ParentTetracarboxylic acids and derivatives
Alternative Parents
Substituents
  • Tetracarboxylic acid or derivatives
  • Biphenyl
  • Benzylether
  • Benzimidazole
  • Phenylmethylamine
  • Benzoyl
  • Alkyl aryl ether
  • Benzenoid
  • N-substituted imidazole
  • Carbonic acid diester
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous amide
  • Oxadiazole
  • Imidazole
  • Azole
  • 1,2,4-oxadiazole
  • Carboxylic acid ester
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationTreatment of hypertension (alone or as an adjunct).
PharmacodynamicsAzilsartan medoxomil decreases the pressor effect of angiotensin II. In response, angiotensin I, angiotensin II, and renin are increased while aldosterone is decreased.
Mechanism of actionAzilsartan medoxomil blocks the angiotensin II type 1 receptor preventing angiotensin II from binding and causing vasoconstriction. Azilsartan's ability to remain tightly bound to AT1 receptors for very long periods after drug washout is among its most unusual features.
Related Articles
AbsorptionAzilsartan medoxomil is hydrolyzed to the active metabolite azilsartan in the GI tract. The presence of food does not affect oral absorption of azilsartan medoxomil, and the bioavailability is 60% for azilsartan. Maximum plasma concentrations are reached in 1.5 to 3 hours.
Volume of distribution

Azilsartan medoxomil has a Vd of 16L.

Protein bindingAzilsartan medoxomil is 99% plasma protein bound.
Metabolism

Azilsartan is metabolized by CYP2C9. CYP2C9 carries out decarboxylation of azilsartan to M-I, and O-dealkylation of azilsartan to M-II. Both M-I and M-II have no pharmacologic activity.

Route of eliminationRenal clearance is 2.3 L/minute.
Half lifeThe half-life is 11 hours, and it takes about 5 days to reach steady state concentrations.
Clearance

Fecal elimination accounts for 55%, urine excretion 42%, and unchanged drug 15%.

ToxicityHypotension and diarrhea are most common.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.915
Caco-2 permeable-0.5843
P-glycoprotein substrateSubstrate0.5619
P-glycoprotein inhibitor INon-inhibitor0.5061
P-glycoprotein inhibitor IINon-inhibitor0.7217
Renal organic cation transporterNon-inhibitor0.8851
CYP450 2C9 substrateNon-substrate0.834
CYP450 2D6 substrateNon-substrate0.8338
CYP450 3A4 substrateSubstrate0.5128
CYP450 1A2 substrateNon-inhibitor0.7445
CYP450 2C9 inhibitorInhibitor0.5531
CYP450 2D6 inhibitorNon-inhibitor0.8779
CYP450 2C19 inhibitorInhibitor0.5915
CYP450 3A4 inhibitorInhibitor0.8507
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.594
Ames testNon AMES toxic0.5227
CarcinogenicityNon-carcinogens0.7059
BiodegradationNot ready biodegradable0.9962
Rat acute toxicity2.5320 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8853
hERG inhibition (predictor II)Non-inhibitor0.6952
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral40 mg/1
Tabletoral40 mg
Tabletoral80 mg/1
Tabletoral80 mg
Tabletoral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7157584 No2005-05-222025-05-22Us
US7572920 No2005-01-072025-01-07Us
US9066936 No2008-03-262028-03-26Us
US9169238 No2010-02-252030-02-25Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point212-214Not Available
water solubilitypractically insolubleNot Available
pKa6.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00703 mg/mLALOGPS
logP4.94ALOGPS
logP6.03ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)9.21ChemAxon
pKa (Strongest Basic)1.75ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area139.57 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity149.52 m3·mol-1ChemAxon
Polarizability57.73 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T: Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem. 1996 Dec 20;39(26):5228-35.

General References
  1. Jones JD, Jackson SH, Agboton C, Martin TS: Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker. P T. 2011 Oct;36(10):634-40. [PubMed:22346296 ]
  2. Lanier G, Sankholkar K, Aronow WS: Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists. Am J Ther. 2014 Sep-Oct;21(5):419-35. doi: 10.1097/MJT.0b013e31824a0ed7. [PubMed:22975662 ]
  3. Kurtz TW, Kajiya T: Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag. 2012;8:133-43. doi: 10.2147/VHRM.S22595. Epub 2012 Feb 28. [PubMed:22399858 ]
External Links
ATC CodesC09CA09C09DA09
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (381 KB)
MSDSDownload (34.9 KB)
Interactions
Drug Interactions
Drug
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Azilsartan medoxomil.
AceclofenacThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Aceclofenac.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Azilsartan medoxomil.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Adapalene.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Azilsartan medoxomil.
AliskirenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Aliskiren.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Azilsartan medoxomil.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Azilsartan medoxomil.
AmobarbitalAmobarbital may increase the hypotensive activities of Azilsartan medoxomil.
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Azilsartan medoxomil.
AntipyrineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Antipyrine.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Azilsartan medoxomil.
ApremilastThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Apremilast.
ArdeparinArdeparin may increase the hyperkalemic activities of Azilsartan medoxomil.
AripiprazoleAripiprazole may increase the hypotensive activities of Azilsartan medoxomil.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Azilsartan medoxomil.
AzapropazoneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Azelastine.
BalsalazideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Balsalazide.
BarbitalBarbital may increase the hypotensive activities of Azilsartan medoxomil.
BemiparinBemiparin may increase the hyperkalemic activities of Azilsartan medoxomil.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Azilsartan medoxomil.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Azilsartan medoxomil.
BenoxaprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Benoxaprofen.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Azilsartan medoxomil.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Azilsartan medoxomil.
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Azilsartan medoxomil.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Azilsartan medoxomil.
BromfenacThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bromfenac.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Azilsartan medoxomil.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Azilsartan medoxomil.
CanagliflozinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Azilsartan medoxomil.
CandoxatrilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Candoxatril.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Azilsartan medoxomil.
CarprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Carprofen.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Azilsartan medoxomil.
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Azilsartan medoxomil.
CastanospermineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Celecoxib.
CertoparinCertoparin may increase the hyperkalemic activities of Azilsartan medoxomil.
ChloroquineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Azilsartan medoxomil.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Azilsartan medoxomil.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Azilsartan medoxomil.
CiprofloxacinAzilsartan medoxomil may increase the arrhythmogenic activities of Ciprofloxacin.
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Azilsartan medoxomil.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Azilsartan medoxomil.
ClonixinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Clonixin.
CyclosporineAzilsartan medoxomil may increase the hyperkalemic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with D-Limonene.
DalteparinDalteparin may increase the hyperkalemic activities of Azilsartan medoxomil.
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Azilsartan medoxomil.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Azilsartan medoxomil.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Azilsartan medoxomil.
DiclofenacThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Azilsartan medoxomil.
DiflunisalThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Diflunisal.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Azilsartan medoxomil.
DinutuximabThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Azilsartan medoxomil.
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Azilsartan medoxomil.
DrospirenoneAzilsartan medoxomil may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Droxicam.
DuloxetineAzilsartan medoxomil may increase the orthostatic hypotensive activities of Duloxetine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Azilsartan medoxomil.
EnalaprilatThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Azilsartan medoxomil.
EpirizoleThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Azilsartan medoxomil.
EplerenoneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Eplerenone.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azilsartan medoxomil.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Azilsartan medoxomil.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Azilsartan medoxomil.
EtanerceptThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with exisulind.
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Azilsartan medoxomil.
FenbufenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Flurbiprofen.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Azilsartan medoxomil.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Azilsartan medoxomil.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Azilsartan medoxomil.
HeparinHeparin may increase the hyperkalemic activities of Azilsartan medoxomil.
HexobarbitalHexobarbital may increase the hypotensive activities of Azilsartan medoxomil.
HMPL-004The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with HMPL-004.
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Azilsartan medoxomil.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Azilsartan medoxomil.
IbuprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Icatibant.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Azilsartan medoxomil.
IndomethacinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Azilsartan medoxomil.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Azilsartan medoxomil.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Azilsartan medoxomil.
IsoxicamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Azilsartan medoxomil.
KebuzoneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ketorolac.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Azilsartan medoxomil.
LeflunomideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Leflunomide.
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Azilsartan medoxomil.
LevodopaAzilsartan medoxomil may increase the orthostatic hypotensive activities of Levodopa.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Azilsartan medoxomil.
LithiumThe serum concentration of Lithium can be increased when it is combined with Azilsartan medoxomil.
LornoxicamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Azilsartan medoxomil.
LoxoprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Loxoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Magnesium salicylate.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Azilsartan medoxomil.
MasoprocolThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Masoprocol.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Azilsartan medoxomil.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mesalazine.
MetamizoleThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Metamizole.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Azilsartan medoxomil.
MethohexitalMethohexital may increase the hypotensive activities of Azilsartan medoxomil.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Azilsartan medoxomil.
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Azilsartan medoxomil.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Azilsartan medoxomil.
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Azilsartan medoxomil.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Azilsartan medoxomil.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Azilsartan medoxomil.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Azilsartan medoxomil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Azilsartan medoxomil.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nabumetone.
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Azilsartan medoxomil.
NadroparinNadroparin may increase the hyperkalemic activities of Azilsartan medoxomil.
NaftifineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with NCX 4016.
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Azilsartan medoxomil.
NepafenacThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Azilsartan medoxomil.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Azilsartan medoxomil.
NicorandilNicorandil may increase the hypotensive activities of Azilsartan medoxomil.
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Azilsartan medoxomil.
Niflumic AcidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nimesulide.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Azilsartan medoxomil.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Azilsartan medoxomil.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Azilsartan medoxomil.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Azilsartan medoxomil.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Azilsartan medoxomil.
OlopatadineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Olsalazine.
OmapatrilatThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Omapatrilat.
OrgoteinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Orgotein.
OxaprozinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxaprozin.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxyphenbutazone.
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Azilsartan medoxomil.
ParecoxibThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Parecoxib.
ParnaparinParnaparin may increase the hyperkalemic activities of Azilsartan medoxomil.
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Azilsartan medoxomil.
PentobarbitalPentobarbital may increase the hypotensive activities of Azilsartan medoxomil.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Azilsartan medoxomil.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Azilsartan medoxomil.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Phenylbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Pimecrolimus.
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Azilsartan medoxomil.
PirfenidoneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Piroxicam.
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Azilsartan medoxomil.
PrimidonePrimidone may increase the hypotensive activities of Azilsartan medoxomil.
PropacetamolThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Propacetamol.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Azilsartan medoxomil.
PTC299The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Azilsartan medoxomil.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Azilsartan medoxomil.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Azilsartan medoxomil.
RescinnamineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Rescinnamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Azilsartan medoxomil.
ResveratrolThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Azilsartan medoxomil.
RiociguatThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Riociguat.
RisperidoneAzilsartan medoxomil may increase the hypotensive activities of Risperidone.
RofecoxibThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Rofecoxib.
SalicylamideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salsalate.
SecobarbitalSecobarbital may increase the hypotensive activities of Azilsartan medoxomil.
SeratrodastThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Seratrodast.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Azilsartan medoxomil.
SpiraprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Azilsartan medoxomil.
SRT501The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with SRT501.
SulfasalazineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Suprofen.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azilsartan medoxomil.
TemocaprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Temocapril.
TenoxicamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Azilsartan medoxomil.
TeriflunomideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Teriflunomide.
ThiamylalThiamylal may increase the hypotensive activities of Azilsartan medoxomil.
ThiopentalThiopental may increase the hypotensive activities of Azilsartan medoxomil.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tiaprofenic acid.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Azilsartan medoxomil.
TinzaparinTinzaparin may increase the hyperkalemic activities of Azilsartan medoxomil.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Azilsartan medoxomil.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tolmetin.
TolvaptanTolvaptan may increase the hyperkalemic activities of Azilsartan medoxomil.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Azilsartan medoxomil.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Azilsartan medoxomil.
TranilastThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tranilast.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Azilsartan medoxomil.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Azilsartan medoxomil.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Valdecoxib.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Azilsartan medoxomil.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Azilsartan medoxomil.
ZaltoprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Zomepirac.
Food Interactions
  • Food does not affect absorption or bioavailibity.
  • Nutrition/Herbal interaction

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Miura S, Matsuo Y, Nakayama A, Tomita S, Suematsu Y, Saku K: Ability of the new AT1 receptor blocker azilsartan to block angiotensin II-induced AT1 receptor activation after wash-out. J Renin Angiotensin Aldosterone Syst. 2014 Mar;15(1):7-12. doi: 10.1177/1470320313482170. Epub 2013 Apr 5. [PubMed:23563275 ]
Comments
comments powered by Disqus
Drug created on December 21, 2012 10:01 / Updated on September 29, 2016 02:27